| 引用本文：鲁全, 苏泽瑞, 王琬.医疗保障制度对本土创新药发展的支持政策研究[J].中国卫生政策研究,2020,13(6):1-7 |
|
| 医疗保障制度对本土创新药发展的支持政策研究 |
| 投稿时间：2020-04-26 修订日期：2020-05-09 PDF全文浏览 HTML全文浏览 |
| 鲁全1, 苏泽瑞1, 王琬2 |
1. 中国人民大学中国社会保障研究中心 北京 100872;
2. 对外经济贸易大学保险学院 北京 100029 |
| 摘要:医疗保障与药品行业之间的关系需要从战略购买者向战略合作者转变，医疗保障制度不仅要发挥第三方支付的功能，实现“以量换价”，也要通过支持创新药的发展间接实现医疗保障制度的长期可持续发展。文章通过对部分发达国家创新药品医保政策的分析和特点总结，对我国本土创新药品医保政策的完善提出了政策建议。 |
| 关键词:医疗保障 本土创新药 国际经验 |
|
| Research on health security policies for supporting the domestic innovative drugs development |
| LU Quan1, SU Ze-rui1, WANG Wan2 |
1. Social Security Research Center, Renmin University of China, Beijing 100872, China;
2. University of International Business and Economics, School of Insurance and Economics, Beijing 100029, China |
| Abstract:The relationship between health security and the pharmaceutical industry needs to change from a strategic buyer to a strategic collaborator. The social health insurance should play not only the role of most important buyer of drugs to achieve the "price-for-value", but also should support the innovation and development of domestic drug industry. By analyzing and summarizing the characteristics of reimbursement policy for innovative drugs abroad, this article puts forward policy recommendations for the improvement of health security of domestically produced innovative drugs. |
| Key words:Health security Domestic innovative drugs International experience |
| 摘要点击次数: 1349 全文下载次数: 855 |
|
|
